Pfizer remains a strong buy as it reaffirms and raises its guidance, driven by operational growth of acquired assets at 18%. The company's robust pipeline, especially in obesity treatment and Vyndamax, supports growth beyond the 2028 loss of exclusivity period. Valuation metrics are attractive, with a P/E of 9.11, EV/EBITDA of 8.29, and a 6.19% dividend yield. Although risks like margin pressure and pricing reversals for Eliquis exist, Pfizer's cost management and pipeline momentum underpin a positive outlook.
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
Pfizer offers a high 5.7% dividend yield compared to Merck's 2.2%, but Pfizer's dividend payout exceeds its free cash flow, signaling risk. Merck's dividend is covered comfortably by free cash flow and has grown steadily since 2020, making it a safer...
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
Five companies—Coca-Cola, Colgate-Palmolive, AT&T, Dominion Energy, and Pfizer—offer dividend stocks that provide steady income with less market volatility, ideal for investors seeking stability. These companies sell essential products or services th...
